Genmab shares jumped 7% in Friday morning trading on the Copenhagen Stock Exchange, adding approximately DKK 9 billion to the company's market capitalization.
The sharp move reflects sustained investor enthusiasm following the release of robust results from a pivotal Phase 3 clinical trial late Monday, which Handelsavisen previously reported as a key catalyst for the stock's recent performance.
The rally underscores the market's positive reception of the clinical data, which centers on the firm's key antibody therapies.
Investors appear to be positioning ahead of the weekend, driving volume and price momentum in the absence of new corporate announcements.
The price action highlights the sensitivity of biotech valuations to late-stage trial outcomes, with Genmab benefiting from the confirmation of its development pipeline's strength.
This development follows a period of heightened activity for the Danish biotech leader, as markets digest the implications of the trial results for future revenue streams and regulatory approvals.
The sustained upward pressure on the share price suggests that traders view the data as a significant de-risking event for the company's near-term outlook.